Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
ZYCUBO ® is now the first and only therapy approved for the treatment of Menkes disease in the United States Sentynl Therapeutics Inc. (“Sentynl”), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited (“Zydus Group”), announced that the U.S. Food and Drug Administration (“FDA”) has approved ZYCUBO® (copper histidinate) for the treatment of Menkes disease […]